Drug resistance associates with activation of Nrf2 in MCF‐7/DOX cells, and wogonin reverses it by down‐regulating Nrf2‐mediated cellular defense response
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Acquired resistance to doxorubicin (DOX) is a serious therapeutic problem in breast cancer patients. In this study, we investigated whether nuclear factor erythroid 2‐related factor 2 (Nrf2) was associated with drug resistant in DOX resistant MCF‐7 (MCF‐7/DOX) cells, and if wogonin, a flavonoid isolated from the root of Scutellaria baicalensis Georgi, could reverse drug resistance in MCF‐7/DOX cells. We found that the endogenous expression of Nrf2 as well as its target proteins heme oxygenase‐1 (HO‐1), NADP(H):quinone oxidoreductase (NQO) in MCF‐7/DOX cells was higher than that in MCF‐7 cells. Tert‐butylhydroquinone treatment increased the expression Nrf2, HO‐1, and NQO‐1, and enhanced resistance of MCF‐7 cells to DOX. Similarly, intracellular Nrf2 protein level was significantly decreased in MCF‐7/DOX cells and DOX resistance was partially reversed by Nrf2 siRNA. Wogonin downregulated the Nrf2‐dependent response and partly reversed DOX resistance in MCF‐7/DOX cells. These results suggested that activation of Nrf2 was associated with drug resistance in MCF‐7/DOX cells. Wogonin reversed drug resistance and its reversal mechanism might be due to the suppression of Nrf2 signaling pathway, indicating the feasibility of using Nrf2 inhibitors to increase efficacy of chemotherapeutic drugs. © 2012 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Nrf2–Keap1 defines a physiologically important stress response mechanism
Motohashi, H., & Yamamoto, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.003 · Cited by 1,725 · cited 1×
“Nrf2 plays a pivotal role in regulating cellular redox homeostasis and protects cells from oxidative or electrophilic stresses [5].”
BackgroundStructure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling
Lo, S., Li, X., Henzl, M. T., Beamer, L. J., & Hannink, M. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601243 · Cited by 604 · cited 1×
“Nrf2 is negatively regulated by Kelchlike ECH-associated protein 1 (Keap1) [11].”
Background
Cited by
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Modulating NRF2 in Disease: Timing Is Everything
Dodson, M., de la Vega, M. R., Cholanians, A. B., Schmidlin, C. J., Chapman, E., & Zhang, D. D. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021856 · Cited by 522
Activators and inhibitors of NRF2: a review of their potential for clinical development
Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., & Cuadrado, A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9372182 · Cited by 413
Liao, H., Ye, J., Gao, L., & Liu, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110917 · Cited by 333
The role of oxidative stress on breast cancer development and therapy
Hecht, F., Pessoa, C. F., Gentile, L. B., Rosenthal, D., Carvalho, D. P., & Fortunato, R. S. (2016) · Tumor Biology · doi:10.1007/s13277-016-4873-9 · Cited by 303
The Nrf2/HO‐1 Axis in Cancer Cell Growth and Chemoresistance
Furfaro, A. L., Traverso, N., Domenicotti, C., Piras, S., Moretta, L., Marinari, U. M., Pronzato, M. A., & Nitti, M. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1958174 · Cited by 295
Thirty years of NRF2: advances and therapeutic challenges.
Zhang, D. D. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01145-0 · Cited by 282
Zhu, J., Wang, H., Chen, F., Fu, J., Xu, Y., Hou, Y., Kou, H. H., Zhai, C., Nelson, M. B., Zhang, Q., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.09.010 · Cited by 162
Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer
Kim, E. H., Jang, H., Shin, D., Baek, S. H., & Roh, J.-L. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1284-8 · Cited by 77
Involvement of NRF2 in Breast Cancer and Possible Therapeutical Role of Polyphenols and Melatonin
Tascioglu Aliyev, A., Panieri, E., Stepanić, V., Gurer-Orhan, H., & Saso, L. (2021) · Molecules · doi:10.3390/molecules26071853 · Cited by 50
“showed that wogonin treatment remodulates increased the NRF2, HO-1 and NQO1 protein levels in doxorubicinresistant MCF-7 cells [79].”
Background
Metadata
- Authors
- Zhong, Y., Zhang, F., Sun, Z., Zhou, W., Li, Z., You, Q., Guo, Q., & Hu, R.
- Venue
- Molecular Carcinogenesis
- Publisher
- Wiley
- Published
- 2012-05-16
- Volume
- 52
- Issue
- 10
- Pages
- 824-834
- ISSN
- 0899-1987 (ISSN-L)
- 1098-2744
- OpenAlex
- W2108417479
- Cited by
- 110
- References
- 3
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.